Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung

[1] Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.10.3322/caac.20107Search in Google Scholar

[2] Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO ClinicalSearch in Google Scholar

[3] Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24 (6): vi99- vi105.10.1093/annonc/mdt178Search in Google Scholar

[4] Li X, Wei S, Chen J. Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules. Onco Targets Ther. 2014;7:937-45.Search in Google Scholar

[5] Swisher SG. Surgical treatment of locally advanced non-small cell lung cancer. In: Fossella FV, Komaki R, Putnam JB Jr, eds. Lung Cancer. New York, NY: Springer, 2002: 118-41.Search in Google Scholar

[6] Peters S, Adjei AA, Gridelli C, et al. Metastatic nonsmall- cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012; 23 (7): vii56- vii64.10.1093/annonc/mds226Search in Google Scholar

[7] National Institute for Health and Clinical Excellence. Pemetrexed for the maintenance treatment of non-small-cell lung cancer. TA190. June 2010. Available at: http://www.nice.org.uk/guidance/TA190.Search in Google Scholar

[8] Paz-Ares LG, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-smallcell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012; 13(3):247-55.10.1016/S1470-2045(12)70063-3Search in Google Scholar

[9] Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31(23):2895-902.10.1200/JCO.2012.47.110223835707Search in Google Scholar

[10] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.20510655437Search in Google Scholar

[11] Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 8/2006 update. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed March, 2014).Search in Google Scholar

[12] Oken, MM, Creech, RH, Tormey DC, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-655.10.1097/00000421-198212000-00014Search in Google Scholar

[13] Minami S, Kijima T, Komuta K, et al. Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated nonsquamous non-small cell lung cancer. Anticancer Res. 2013; 33(12):5535-42.Search in Google Scholar

[14] Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006; 52:155-163.10.1016/j.lungcan.2006.01.00616569462Search in Google Scholar

[15] Belani CP, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine carboplatin (G-Cb) for patients with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol. 2010; 28:540s.10.1200/jco.2010.28.15_suppl.7506Search in Google Scholar